SCHOTT Pharma has held its Annual General Meeting for the Fiscal Year 2024. The virtual Annual General Meeting enabled shareholders to interact directly with the Management and Supervisory Boards and ask questions. Together, they reflected on the strong fiscal year 2024, in which SCHOTT Pharma exceeded its targets, including its previously raised revenue guidance, and thus accelerated its trajectory of profitable growth.
In 2024, right before celebrating its first anniversary as a publicly listed company, SCHOTT Pharma was promoted to the MDAX, underlining its strong performance during the twelve months since its IPO in 2023. The current environment, including growth opportunities and market challenges was also discussed, highlighting a cautious, but optimistic perspective for FY 2025.
All structural market trends that pose growth opportunities are showing ongoing strong dynamics: These include the continued high demand for GLP-1 and mRNA drugs, as well as the ongoing commercialization of ADCs and home-care solutions, supporting the strategic shift of SCHOTT Pharma towards high-value solutions
In total, approximately 97 percent of the share capital was represented. The shareholders voted in favour of all items on the agenda, including the appointment of Dr. Wolfram Carius to SCHOTT Pharma’s Supervisory Board and the installation of KPMG as the company’s new auditor.
“This year’s Annual General Meeting gave us a great opportunity to look back on another successful year for SCHOTT Pharma, together with our shareholders, and to provide an insight into the months ahead,” said Andreas Reisse, CEO of SCHOTT Pharma. “The confidence expressed by the capital markets underscores that we have set the right course: we will continue our profitable growth trajectory. Our innovative products, global footprint and market position as a trusted partner to leading pharma companies put us in a strong position to successfully address the most important pharma trends.”
“SCHOTT Pharma is a growth-oriented company,” said Dr. Almuth Steinkühler, CFO of SCHOTT Pharma. “We want our shareholders to participate in our profitable growth and are therefore distributing a dividend of EUR 0.16 per share. Despite a challenging market environment, we are convinced that our strategic focus on high-value solutions will continue to enable sustainable, profitable growth.”
The full report is available here.